BVX 20Alternative Names: BVX-20 antibody; BVX20; BVX20 MAb; BVX20-CD20 antibody - Biocon/Vaccinex
Latest Information Update: 17 Feb 2016
At a glance
- Originator Biocon; Vaccinex
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action CD20 antigen inhibitors; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
Most Recent Events
- 15 Dec 2011 Phase-I/II clinical trials in Non-Hodgkin's lymphoma in India (IV)